CRF2 Agonist for the Treatment of Worsening Heart Failure
NCT06815471
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Worsening Heart Failure
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Corteria Pharmaceuticals
- Last updated on ClinicalTrials.gov
- November 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
North Carolina · 1
- NC Heart and Vascular Research, LLC · Raleigh, NC
Ohio · 1
- Ohio State University · Columbus, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.